Browsing Tag
ASC36
3 posts
Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity
Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next.
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.